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We thank Dr. Fournier and his colleagues for theirdialysis patients
interest in our recently published study [1] and would
like to offer the following answers to their comments.
To the Editor: In a recent issue of Kidney Interna- Nephrologists face the challenge of differentiating low
tional, Monier-Faugere et al [1] clearly demonstrated the bone turnover from normal-high bone turnover because
superiority of the parathyroid hormone (1-84) PTH/C- of the immediate therapeutic ramifications, that is, nor-
PTH fragment ratio in predicting bone turnover. How- mal-high bone turnover should be treated with vitamin
ever, we wonder why the authors were only interested D while low bone turnover is not amenable to vitamin D
by the diagnosis of low bone turnover since their patients treatment. Vitamin D therapy in patients with adynamic
had normal plasma calcium while taking calcium carbon- bone disease is associated with elevation in calcium phos-
ate (CaCO3) but no calcitriol and had not been exposed phate product, secondary to improved intestinal calcium
to aluminum phosphate binder. Indeed, in such patients, absorption with inability to maintain normal bone cal-
low bone turnover is not an actual bone disease, in con- cium accretion [2]. It is generally accepted that uncon-
trast to what occurs in patients with previous aluminum trolled calcium phosphate product is associated with in-
overload [2]. In the present study, the major clinical creased cardiovascular calcifications and mortality. It is
concern is hyperphosphatemia, and this abnormality was not justified to assume absence of disease merely because
worse in the group with normal or high bone turnover of presence of normal serum calcium.
since it was 7.1 mg/dL, that is, above 6.5, the threshold The described diagnostic approach for low bone turn-
for which an increased mortality risk has been observed over inherently allows the recognition of normal-high
[3]. It would have been more clinically relevant to know bone turnover by exclusion.
whether hyperphosphatemia was associated with high We are sorry that Dr. Fourner et al are disappointed
bone turnover and to show the superiority of their ratio that serum phosphorus levels are not diagnostic for bone
for this latter diagnosis. With the Biosource RIA, using turnover but our data simply support statistically a well-
the Bouillon antibodies that also measures (1-84) PTH known clinical observation.
at the exclusion of (7-84) PTH, we reported in 1991 that
Marie-Claude Monier-Faugere andin 23 hemodialysis patients never exposed to aluminum,
Hartmut H. Malluche, for the authorsthe nine patients with osteitis fibrosa had levels above
Lexington, Kentucky1.7, the upper limit of normal, whereas all the six patients
with low turnover had levels below this limit [4]. Out of Correspondence to: Hartmut Malluche, M.D., Division of Nephrol-
ogy, Bone and Mineral Metabolism, University of Kentucky Medicalthe eight patients with normal turnover, three had levels
Center, Room MN 564, Lexington, KY 40536-0084, USA.between 1.0 and 1.7 this limit, four within the normal
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range and one below this range.
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